China's largest private physical-examination (health check-up) chain, serving individual and corporate clients.
China's largest private physical-examination (health check-up) chain, serving individual and corporate clients.
Sells check-up packages, many of them booked by employers for staff, with individuals paying directly for the rest, so revenue follows the number of exams and add-on tests sold. It runs a mix of owned and partner centers.
In one line: A Chinese Concentra-style preventive health check-up chain.
Moat: narrow (scale, brand, distribution). Largest branch network gives scale and brand recognition in a fragmented market.
Headquarters: Hangzhou, Zhejiang, China · Employees: 33,119
Size Meinian Onehealth Healthcare (002044.SZ) is a China Health Care company (Medical/Nursing Services) with a market value of $2.60B, the 912th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.57 on 18 Nov 2026.
Performance Over six months the shares fell 26.6%, against +19.1% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +11.5%); the operating margin is 8.8% (peer median 8.2%).
Valuation It trades at 49.6× forward earnings against a peer median of 37.6× (8th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.5 points above its cost of capital (8.4% WACC).
Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.0B | CN¥10.4B | CN¥10.7B | CN¥10.9B | CN¥8.61B |
| Revenue growth | — | -3% | -2% | +26% | — |
| Gross profit | CN¥5.11B | CN¥4.23B | CN¥4.53B | CN¥4.61B | CN¥2.90B |
| EBITDA | n/a | CN¥2.24B | CN¥2.31B | CN¥2.58B | CN¥1.28B |
| Net income | CN¥330M | CN¥285M | CN¥282M | CN¥506M | -CN¥559M |
| Free cash flow | CN¥1.39B | CN¥1.42B | CN¥1.23B | CN¥1.63B | CN¥1.15B |
| Capital expenditure | CN¥496M | CN¥419M | CN¥446M | CN¥408M | CN¥425M |
| Total debt | CN¥6.06B | CN¥6.67B | CN¥6.85B | CN¥6.25B | CN¥5.81B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002044.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.5% | -3.4% | 8th lowest of 21 |
| 6-month return | -26.6% | +19.1% | 2nd lowest of 21 |
| Distance from 52-week high | -48.5% | -14.8% | 3rd lowest of 21 |
| Revenue growth (TTM) | -4.5% | +11.5% | 2nd lowest of 21 |
| Operating margin | 8.8% | 8.2% | 9th highest of 21 |
| Forward P/E | 49.6× | 37.6× | 8th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 4.2% | 20.4% | 5th least demanding of 15 |
| Growth delivered (Del g) | +5.7% | +11.0% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | -1.5 pp | +3.9 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +1.5 pp | -1.6 pp | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 49.6× | 4.2% | +5.7% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| Acadia Healthcare ACHC | United States | $3.49B | +56% | +4% | 10% | 18.6× | n/a | n/a |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.53B | +15% | +17% | 24% | 50.5× | 32.3% | +11.8% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Medicover MCOV-B.ST | Sweden | $3.87B | +21% | +3% | 7% | 36.1× | 19.6% | +20.2% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Hims & Hers Health HIMS | United States | $4.00B | -26% | +30% | -1% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| BillionToOne BLLN | United States | $4.37B | +7% | +72% | 10% | 115.3× | 22.8% | +71.9% |